1W Return
1M Return
6M Return
1Y Return
3Y Return
Start SIP in Transgene Biotek
Transgene Biotek Stock Performance
52 Week Low - High
Today’s Low - High
Open
Prev. Close
Total Traded Value
Transgene Biotek Fundamental
Market Cap (in crs)
Face Value
Turnover (in lacs)
Key Metrics
Qtr Change %
66.05% Fall from 52W High
-21.5
Dividend yield 1yr %
0
Transgene Biotek Key Financials
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
*All values are in ₹ Cr.
Transgene Biotek Quarterly Revenue
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|
0.08 Cr | 0.06 Cr | 0.05 Cr | 0.04 Cr | 0.04 Cr |
Transgene Biotek Yearly Revenue
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|
0.42 Cr | 0.23 Cr | 0.3 Cr | 0.44 Cr | 0.18 Cr | 2.11 Cr |
Transgene Biotek Quarterly Net Profit/Loss
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|
-0.09 Cr | -0.07 Cr | 0.2 Cr | -0.27 Cr | -0.12 Cr |
Transgene Biotek Yearly Net Profit/Loss
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|
-0.66 Cr | -6.01 Cr | -10.4 Cr | -10.43 Cr | -10.96 Cr | -8.79 Cr |
Transgene Biotek Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
Current Price
5Day EMA
3.80
10Day EMA
3.80
12Day EMA
3.80
20Day EMA
3.80
26Day EMA
3.80
50Day EMA
4.00
100Day EMA
4.70
200Day EMA
5.70
5Day SMA
3.80
10Day SMA
3.80
20Day SMA
3.70
30Day SMA
3.70
50Day SMA
3.90
100Day SMA
4.80
150Day SMA
5.60
200Day SMA
6.40
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 883 Rs | 883 Rs |
Week Rs | 1736 Rs | 1736 Rs |
Month Rs | 15772 Rs | 15772 Rs |
Resistance & Support
3.68
Pivot
Resistance
First Resistance
3.68
Second Resistance
3.68
Third Resistance
3.68
Support
First Support
3.68
Second support
3.68
Third Support
3.68
Relative Strength Index
42.77
Money Flow Index
78.33
MACD
-0.02
MACD Signal
-0.03
Average True Range
0.13
Average Directional Index
13.66
Rate of Change (21)
5.44
Rate of Change (125)
-45.72
Similar stocks
Similar Stocks
Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
27.88 | 3.22 | 10.84 | 3.75 | -5.88% | 9.85% | -46.51% | -48.02% | 4.25% | 0.00% | 0.00 | 46.85 | -4.13 | ||
GKB Ophthalmics Ltd. | 71.55 | - | - | - | - | - | - | - | - | - | - | - | - | |
Family Care Hospitals Ltd. | 4.71 | - | - | - | - | - | - | - | - | - | - | - | - | |
Samsrita Labs Ltd. | 21.88 | - | - | - | - | - | - | - | - | - | - | - | - | |
Sharma East India Hospitals & Medical Research Ltd. | 75.62 | - | - | - | - | - | - | - | - | - | - | - | - | |
Deccan Health Care Ltd. | 18.16 | - | - | - | - | - | - | - | - | - | - | - | - | |
Gian Life Care Ltd. | 16.18 | - | - | - | - | - | - | - | - | - | - | - | - |
Transgene Biotek Company background
Founded in: 1990
Managing director: K Koteswara Rao
Founded in March, 1990 by Dr. Koteswara Rao, Transgene Biotek Ltd was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc. The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune.Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immunodiagnostic reagents for qualitative and quantitative estimation of biochemical parameters and diagnosis of diseases respectively.Transgene Bioteks products are exported to Africa, Russia, China, Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility costing Rs. 30 crore at the Anrich Industrial Area, Bollaram. TBL is working of four new plants comprising of Oral deliver of proteins and peptides DNA vaccines fusion proteins and bio therapeutics. The new project is funded through preferential offer to Batterymarch Financial Management USA and Other Financial Institutions (FIs).The Company absorbed the transfer of technology from RBB Inc, USA for the manufacture and marketing of Erythropoietin during year 2003. The Scheme of Arrangement for Amalgamation of M/S Saket Biotechnologies Private Limited (SBPL) with the Company was implemented and made effective on 7th February, 2005. In terms of the said Scheme of Amalgamation, 60,60,000 Equity Shares were allotted to the Sharesholders of M/S Saket Biotechnologies Private limited on 27 April 2005.In 201213, the Company started the commercial production of Omega3 DHA (Docosahexaenoic Acid) . It formulated the molecule belonging to a very large global pharma company for undergoing studies at its own chosen facilities in USA during year 202021. Transgene has been developing novel oral and nasal formulations for the delivery of various protein and peptidebased biologicals through oral and intranasal routes. Transgene is focused on developing novel therapies in the areas of Oncology, AutoImmune diseases and new drug delivery technologies, that have the potential to substantially improve the quality of life of patients in areas of unmet medical need.
Transgene Biotek FAQs
How to buy Transgene Biotek shares?
You can easily buy Transgene Biotek shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Transgene Biotek stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account
